Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2011 Dec 22;365(25):2366-76. doi: 10.1056/NEJMoa1111732. Epub 2011 Nov 12.

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

Collaborators (377)

Genuth S, Nathan DM, Zinman B, Crofford O, Crandall J, Reid M, Brown-Friday J, Engel S, Sheindlin J, Martinez H, Shamoon H, Engel H, Phillips M, Gubitosi-Klug R, Mayer L, Pendegast S, Zegarra H, Miller D, Singerman L, Smith-Brewer S, Novak M, Quin J, Dahms W, Genuth S, Palmert M, Brillon D, Lackaye ME, Kiss S, Chan R, Reppucci V, Lee T, Heinemann M, Whitehouse F, Kruger D, Jones JK, McLellan M, Carey JD, Angus E, Thomas A, Galprin A, Bergenstal R, Johnson M, Spencer M, Morgan K, Etzwiler D, Kendall D, Aiello LP, Golden E, Jacobson A, Beaser R, Ganda O, Hamdy O, Wolpert H, Sharuk G, Arrigg P, Schlossman D, Rosenzwieg J, Rand L, Nathan DM, Larkin M, Ong M, Godine J, Cagliero E, Lou P, Folino K, Fritz S, Crowell S, Hansen K, Gauthier-Kelly C, Service J, Ziegler G, Luttrell L, Caulder S, Lopes-Virella M, Colwell J, Soule J, Fernandes J, Hermayer K, Kwon S, Brabham M, Blevins A, Parker J, Lee D, Patel N, Pittman C, Lindsey P, Bracey M, Lee K, Nutaitis M, Farr A, Elsing S, Thompson T, Selby J, Lyons T, Yacoub-Wasef S, Szpiech M, Wood D, Mayfield R, Molitch M, Schaefer B, Jampol L, Lyon A, Gill M, Strugula Z, Kaminski L, Mirza R, Simjanoski E, Ryan D, Kolterman O, Lorenzi G, Goldbaum M, Sivitz W, Bayless M, Counts D, Johnsonbaugh S, Hebdon M, Salemi P, Liss R, Donner T, Gordon J, Hemady R, Kowarski A, Ostrowski D, Steidl S, Jones B, Herman WH, Martin CL, Pop-Busui R, Sarma A, Albers J, Feldman E, Kim K, Elner S, Comer G, Gardner T, Hackel R, Prusak R, Goings L, Smith A, Gothrup J, Titus P, Lee J, Brandle M, Prosser L, Greene DA, Stevens MJ, Vine AK, Bantle J, Wimmergren N, Cochrane A, Olsen T, Steuer E, Rath P, Rogness B, Hainsworth D, Goldstein D, Hitt S, Giangiacomo J, Schade DS, Canady JL, Chapin JE, Ketai LH, Braunstein S, Bourne PA, Schwartz S, Brucker A, Maschak-Carey BJ, Baker L, Orchard T, Silvers N, Ryan C, Songer T, Doft B, Olson S, Bergren RL, Lobes L, Rath PP, Becker D, Rubinstein D, Conrad PW, Yalamanchi S, Drash A, Morrison A, Bernal ML, Vaccaro-Kish J, Malone J, Pavan PR, Grove N, Iyer MN, Burrows AF, Tanaka EA, Gstalder R, Dagogo-Jack S, Wigley C, Ricks H, Kitabchi A, Murphy MB, Moser S, Meyer D, Iannacone A, Chaum E, Yoser S, Bryer-Ash M, Schussler S, Lambeth H, Raskin P, Strowig S, Zinman B, Barnie A, Devenyi R, Mandelcorn M, Brent M, Rogers S, Gordon A, Palmer J, Catton S, Brunzell J, Wessells H, de Boer I, Hokanson J, Purnell J, Ginsberg J, Kinyoun J, Deeb S, Weiss M, Meekins G, Distad J, Van Ottingham L, Dupre J, Harth J, Nicolle D, Driscoll M, Mahon J, Canny C, May M, Lipps J, Agarwal A, Adkins T, Survant L, Pate RL, Munn GE, Lorenz R, Feman S, White N, Levandoski L, Boniuk I, Grand G, Thomas M, Joseph DD, Blinder K, Shah G, Boniuk, Burgess, Santiago J, Tamborlane W, Gatcomb P, Stoessel K, Taylor K, Goldstein J, Novella S, Mojibian H, Cornfeld D, Gubitosi-Klug R, Quin J, Gaston P, Palmert M, Trail R, Dahms W, Lachin J, Cleary P, Backlund J, Sun W, Braffett B, Klumpp K, Chan K, Diminick L, Rosenberg D, Petty B, Determan A, Kenny D, Rutledge B, Younes N, Williams, Dews L, Hawkins M, Cowie C, Fradkin J, Siebert C, Eastman R, Danis R, Gangaputra S, Neill S, Davis M, Hubbard L, Wabers H, Burger M, Dingledine J, Gama V, Sussman R, Steffes M, Bucksa J, Nowicki M, Chavers B, O'Leary D, Polak J, Harrington A, Funk L, Crow R, Gloeb B, Thomas S, O'Donnell C, Soliman E, Zhang ZM, Prineas R, Campbell C, Ryan C, Sandstrom D, Williams T, Geckle M, Cupelli E, Thoma F, Burzuk B, Woodfill T, Low P, Sommer C, Nickander K, Budoff M, Detrano R, Wong N, Fox M, Kim L, Oudiz R, Lima J, Bluemke D, Turkbey E, van der Geest RJ, Liu C, Malayeri A, Jain A, Miao C, Chahal H, Jarboe R, Weir G, Espeland M, Klein B, Manolio T, Rand L, Singer D, Stern M, Boulton AE, Clark C, D'Agostino R, Lopes-Virella M, Garvey WT, Lyons TJ, Jenkins A, Klein R, Virella G, Jaffa A, Carter R, Lackland D, Brabham M, McGee D, Zheng D, Mayfield RK, Paterson A, Boright A, Bull S, Sun L, Scherer S, Zinman B, Maynard J, Natarajan R, Miao F, Zhang L, Chen Z, Nathan DM.

Abstract

BACKGROUND:

An impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population.

METHODS:

In the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy aimed at achieving near-normal glucose concentrations or to conventional diabetes therapy aimed at preventing hyperglycemic symptoms. Subsequently, 1375 participants were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Serum creatinine levels were measured annually throughout the course of the two studies. The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration formula. We analyzed data from the two studies to determine the long-term effects of intensive diabetes therapy on the risk of impairment of the GFR, which was defined as an incident estimated GFR of less than 60 ml per minute per 1.73 m(2) of body-surface area at two consecutive study visits.

RESULTS:

Over a median follow-up period of 22 years in the combined studies, impairment of the GFR developed in 24 participants assigned to intensive therapy and in 46 assigned to conventional therapy (risk reduction with intensive therapy, 50%; 95% confidence interval, 18 to 69; P=0.006). Among these participants, end-stage renal disease developed in 8 participants in the intensive-therapy group and in 16 in the conventional-therapy group. As compared with conventional therapy, intensive therapy was associated with a reduction in the mean estimated GFR of 1.7 ml per minute per 1.73 m(2) during the DCCT study but during the EDIC study was associated with a slower rate of reduction in the GFR and an increase in the mean estimated GFR of 2.5 ml per minute per 1.73 m(2) (P<0.001 for both comparisons). The beneficial effect of intensive therapy on the risk of an impaired GFR was fully attenuated after adjustment for glycated hemoglobin levels or albumin excretion rates.

CONCLUSIONS:

The long-term risk of an impaired GFR was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated with conventional diabetes therapy. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360815 and NCT00360893.).

Comment in

PMID:
22077236
[PubMed - indexed for MEDLINE]
PMCID:
PMC3270008
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk